← Back to Search

Protein Tyrosine Phosphatase Inhibitor

JAB-3068 (SHP2 inhibitor) for Non-Small Cell Lung Cancer

Phase 1
Waitlist Available
Research Sponsored by Jacobio Pharmaceuticals Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 2 years
Awards & highlights

Summary

This trial is testing a new drug to see if it is safe and works against cancer.

Eligible Conditions
  • Non-Small Cell Lung Cancer
  • Head and Neck Cancers
  • Esophageal Cancer
  • Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with dose limiting toxicities
Secondary outcome measures
Area under the curve
Cmax
Duration of response
+4 more
Other outcome measures
pERK

Trial Design

1Treatment groups
Experimental Treatment
Group I: JAB-3068 (SHP2 inhibitor)Experimental Treatment1 Intervention
Daily oral administration of JAB-3068

Find a Location

Who is running the clinical trial?

Jacobio Pharmaceuticals Co., Ltd.Lead Sponsor
20 Previous Clinical Trials
2,214 Total Patients Enrolled
Jacobio PharmaceuticalsStudy DirectorJacobio Pharmaceuticals Co., Ltd.
10 Previous Clinical Trials
1,051 Total Patients Enrolled
~6 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top